Question: Surfaced 2026-05-20 from the r14b Discord salvage (Nolan Cuddihy conviction-doc, 2026-05-13). BANB.SW (Bachem) and LZAGY (Lonza) are already covered on the supply side in trace-glp1-manufacturing.json (added 2026-05-06 from an ambient-browse orphan-mention closure). What's new is a demand-side cultural overlay: the hook is "a company scaling peptide manufacturing is positioned for Looksmaxxing consumer sentiment" — i.e. aesthetic / non-medical demand for GLP-1s and peptides. This is a cross-paradigm bridge: supply-chain (BANB peptide CDMO) × cultural-arbitrage (Looksmaxxing as the demand signal driving aesthetic-injectable adoption). The source row offers two routing options: (a) cultural-thesis gets an explicit glp1-aesthetic-demand sub-thesis citing BANB/LZAGY as upstream beneficiaries; or (b) trace-glp1-manufacturing gets a cultural_demand_signals annotation naming Looksmaxxing as a non-medical demand vector.

Verdict: Combine as an annotation — option (b). Route the cultural signal to trace-glp1-manufacturing as a cultural_demand_signals description annotation. Reject option (a) (no cultural-thesis watchlist add) and reject a new cross-paradigm perspective. Looksmaxxing demand is a demand-breadth vector that broadens the total peptide volume flowing through the same CDMO capacity — it hardens the existing supply-chain bottleneck thesis at the margin but introduces no new mechanism and no new equity vehicle. The mechanism (capacity bottleneck) lives on the supply-chain side; the cultural-arbitrage paradigm is the lens that surfaced the demand context, not a parallel structure to mint.

What we're asking

The source row bundles a routing decision with an implicit thesis claim. Split them:

1. Thesis claim: Does aesthetic / non-medical ("Looksmaxxing") GLP-1 + peptide demand materially change the BANB/LZAGY supply-chain thesis? → a mechanism question.
2. Routing claim: If the signal is real, does it belong as a sub-thesis on the consumer-sentiment watchlist (cultural-thesis), or as a demand annotation on the supply-chain watchlist (trace-glp1-manufacturing)? → an ontology / placement question.

Both have to clear the bar set by an already-adjudicated prior: the protein-economy perspective is CLOSED (retired-with-verdict 2026-05-19), and its closure is the load-bearing precedent here.

What we found

1. The cultural GLP-1 → consumer-equity link was already adjudicated and closed

protein-economy ("GLP-1 Cultural Cascade — Vehicle Pivot HIMS / CVS", paradigm: cultural) was retired-with-verdict on 2026-05-19. The closure reason is precise and directly on-point: the HIMS pivot vehicle was disproven at the catalyst level (semaglutide shortage ended Feb 2025; FDA moved to shut large-scale GLP-1 compounding through 2026; the Novo–Wegovy partnership collapsed into a patent suit + DOJ referral; HIMS swung to a $92M net loss, −68% from its high). The durable "channel beats SKU" idea survived but rotated to LillyDirect / Amazon / Walmart / LifeMD — "no clean pure-play equity vehicle." Successor: null.

The lesson encoded by that closure: cultural GLP-1 demand is real, but it does not route cleanly to a tradeable consumer equity. Looksmaxxing is a different flavor of the same demand story (aesthetic / off-label rather than medical-obesity). It does not come with a new consumer vehicle either. Reviving a cultural-GLP-1 sub-thesis on a single Discord conviction-doc hook would re-litigate a closed verdict without meeting any reopen bar.

2. Categorical mismatch kills the cultural-thesis watchlist add (option a)

cultural-thesis.json is defined as "consumer names that move on cultural sentiment, not just earnings" — BRBR, HIMS, NKE, LULU, SBUX, CROX, DPZ, TSLA. Every member is a Western consumer brand or a consumer-facing telehealth name.

BANB.SW and LZAGY are the opposite class: supply-side peptide CDMOs, foreign-listed (BANB.SW Swiss primary; LZAGY = Lonza ADR), carried research_only. They are upstream manufacturers, not consumer-sentiment names. Adding them to cultural-thesis would (i) violate the watchlist's own definition, (ii) miscategorize the tickers, and (iii) break the repo rule that research-only foreign primaries stay out of watchlist/trade rows unless explicitly authorized (CLAUDE.md). They already sit correctly in trace-glp1-manufacturing. Option (a) is rejected.

3. Looksmaxxing is a demand-breadth annotation, not a new mechanism

The supply-chain thesis is that peptide-synthesis CDMO capacity is the bottleneck (BANB/LZAGY are the world's two largest pure-play peptide CDMOs competing for branded GLP-1 synthesis contracts). The bottleneck is chemistry-and-capacity, and it is agnostic to end-use: a gram of synthesized peptide flows through the same purification (HPLC) / chromatography-resin / synthesis capacity whether it is consumed for medical obesity, for diabetes, or for aesthetic / off-label "looksmaxxing" body-composition use.

So the cultural overlay's effect on the supply-chain thesis is purely additive on the demand side: Looksmaxxing / aesthetic-injectable adoption is one more demand vector stacking onto medical-obesity and diabetes demand → broader, more durable capacity utilization → firmer pricing power for the constrained CDMOs. That hardens the existing thesis at the margin, but it adds no new structural mechanism (the bottleneck was already the point) and no new vehicle (the beneficiaries are the CDMOs already on the trace). That is the textbook shape of a cultural_demand_signals annotation, not a new sub-thesis with its own log.

Event truth vs price truth (kept separate): the Looksmaxxing demand vector is a captured cultural narrative — sourced from the 2026-05-20 r14b Discord conviction-doc and consistent with the broader documented "aesthetic-GLP-1 / peptides-for-looks" trend. It is logged as a demand-context annotation, not as a price or revenue claim about BANB/LZAGY. No broad scan was run; BANB.SW pricing context (52w-high-area, inflecting with the cohort as of the 2026-05-06 coverage close) is carried, not re-fetched.

4. Cross-paradigm bridges annotate the carrier side; they don't mint parallel structures

We maintain three paradigms — supply-chain / picks-and-shovels / cultural-arbitrage — and rarely cross-wire them. The discipline (reinforced by the protein-economy closure and the standing "name a theme, name 3–5 picks, don't proliferate" meta-lesson) is to fold a confirming cross-signal into the side that carries the mechanism, citing the other paradigm as the lens. Here the mechanism (capacity bottleneck) lives on the supply-chain side; cultural-arbitrage is the lens that surfaced an extra demand vector. → annotate trace-glp1-manufacturing; cite cultural-arbitrage as the surfacing lens.

This mirrors the sibling decision from the same r14b salvage batch — 2026-05-26-apr-kbeauty-cultural-thesis-adjacency-check — which registered a coverage gap but deferred rather than spinning up a kbeauty perspective on a single conviction-doc. Same restraint, opposite direction (APR is genuinely a consumer name that could fit cultural-thesis once the doc is read; BANB/LZAGY are supply-side and never fit it).

Verdict + reasoning

Combine via annotation (option b). No new perspective. No cultural-thesis add.

Mutation applied

• stonks/watchlists/trace-glp1-manufacturing.json — appended a cultural_demand_signals note to the description: Looksmaxxing / aesthetic-injectable adoption is a non-medical (off-label, body-composition / aesthetic) demand vector that broadens total peptide volume flowing through the constrained CDMO capacity (BANB.SW / LZAGY), supporting the capacity-bottleneck thesis on the margin. Surfaced 2026-05-20 from r14b Discord salvage (Nolan Cuddihy conviction-doc). Demand context only — not a price/revenue claim, not a new equity vehicle (cf. protein-economy closure 2026-05-19: cultural GLP-1 demand has no clean consumer pure-play), and not added to cultural-thesis (CDMOs are supply-side research_only foreign primaries).

Rejected placements (cited, not owned)

• cultural-thesis.json — evaluated as a home and rejected (categorical mismatch). Cited here; no mutation.
• protein-economy (closed perspective) — cited as the governing precedent; not added to affects.perspectives (it is rejected/closed as a home).

Follow-up trigger (no date)

Reopen the cultural vehicle question only if Looksmaxxing / aesthetic-GLP-1 demand surfaces a publicly-traded consumer pure-play (e.g. an aesthetic-injectable clinic chain or a branded looksmaxxing consumer platform) — that would be a cultural-thesis candidate, distinct from the supply-side CDMO trace. Until then the signal lives as the demand annotation above. No new task filed (trigger-based, conviction-doc-gated).